Copyright
©The Author(s) 2015.
World J Diabetes. Jun 25, 2015; 6(6): 840-849
Published online Jun 25, 2015. doi: 10.4239/wjd.v6.i6.840
Published online Jun 25, 2015. doi: 10.4239/wjd.v6.i6.840
Class | Action mechanism | Glucose target | Drug | Daily dose (mg) |
Sulfonylurea | Increases insulin secretion | Fasting and postprandial | Glipizide | 2.5-10 |
Gliclazide | 40-240 | |||
Gliquidone | 45-60 | |||
Meglitinide | Increases insulin secretion | Postprandial | Repaglinide | 0.5-12 |
Mitiglinide | 7.5-15 | |||
Thiazolidinediones | Insulin sensitizer | Fasting and postprandial | Rosiglitazone | 4-8 |
Pioglitazone | 15-45 | |||
Alpha-glucosidase inhibitor | Delays carbohydrate absorption | Postprandial | Voglibose | 0.6-0.9 |
Acarbose | 75-300 | |||
Miglitol | 150-225 |
- Citation: Nakamura Y, Hasegawa H, Tsuji M, Udaka Y, Mihara M, Shimizu T, Inoue M, Goto Y, Gotoh H, Inagaki M, Oguchi K. Diabetes therapies in hemodialysis patients: Dipeptidase-4 inhibitors. World J Diabetes 2015; 6(6): 840-849
- URL: https://www.wjgnet.com/1948-9358/full/v6/i6/840.htm
- DOI: https://dx.doi.org/10.4239/wjd.v6.i6.840